{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:38:53Z","timestamp":1761917933919,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clinthera.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T01:08:14Z","timestamp":1653354494000},"page":"873-887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States"],"prefix":"10.1016","volume":"44","author":[{"given":"Meredith","family":"Hoog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Peleshok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6521-1007","authenticated-orcid":false,"given":"Michael","family":"Grabner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.04.005_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/2468-8827.184853","article-title":"WHO Global report on diabetes: a summary","volume":"1","author":"Roglic","year":"2016","journal-title":"Int J Noncommun Dis"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0002","first-page":"12","volume":"2020","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"2030: insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0004","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","article-title":"Glycemic targets: standards of medical care in diabetes\u20142021","volume":"44","author":"Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-019-01199-8","article-title":"Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States","volume":"37","author":"Ali","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0007","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2337\/dc20-2439","article-title":"Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88","volume":"44","author":"Lind","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0008","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","article-title":"Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study","volume":"373","author":"Tab\u00e1k","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0009","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/dom.14421","article-title":"Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): a 2-year randomized controlled trial","volume":"23","author":"Retnakaran","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2337\/dc18-0787","article-title":"Impact of insulin and metformin versus metformin alone on \u03b2-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"41","author":"Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0011","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.2337\/dc18-1662","article-title":"Impact of gastric banding versus metformin on \u03b2-cell function in adults with impaired glucose tolerance or mild type 2 diabetes","volume":"41","author":"Xiang","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0012","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/dc17-0589","article-title":"Effects of liraglutide on weight loss, fat distribution, and \u03b2-cell function in obese subjects with prediabetes or early type 2 diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0013","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0014","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s13300-020-00799-w","article-title":"Efficacy and safety of dulaglutide monotherapy compared to glimepiride in oral antihyperglycemic medication-na\u00efve Chinese patients with type 2 diabetes: a post hoc analysis of AWARD-CHN1","volume":"11","author":"Li","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0015","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/dom.12671","article-title":"Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic \u03b2-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes","volume":"18","author":"Mari","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0016","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0017","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.clinthera.2020.06.019","article-title":"The relationship between timing of initiation on a glucagon-like peptide-1 receptor agonist and glycosylated hemoglobin values among patients with type 2 diabetes","volume":"42","author":"Boye","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0019","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40268-019-0273-0","article-title":"Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK","volume":"19","author":"Boye","year":"2019","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus","volume":"43","author":"Reach","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0022","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s13300-020-00839-5","article-title":"Real-world effectiveness of dulaglutide in patients with type 2 diabetes mellitus: a literature review","volume":"11","author":"Robinson","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14195","article-title":"Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data","volume":"23","author":"Mody","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2018.1465903","article-title":"Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes","volume":"34","author":"Matza","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/dom.13902","article-title":"Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)","volume":"22","author":"Matza","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0026","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jgs.13388","article-title":"A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus","volume":"63","author":"Bhattacharya","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0027","first-page":"721","article-title":"Validating the adapted Diabetes Complications Severity Index in claims data","volume":"18","author":"Chang","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0028","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0029","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0030","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0031","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1080\/03007995.2019.1618806","article-title":"Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area","volume":"35","author":"Mata-Cases","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0032","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","article-title":"Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials","volume":"27","author":"DeFronzo","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0033","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc06-1120","article-title":"Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis","volume":"29","author":"Bloomgarden","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0034","first-page":"304","article-title":"Factors associated with diabetes-related clinical inertia in a managed care population and its effect on hemoglobin A1c goal attainment: a claims-based analysis","volume":"25","author":"Ruiz-Negron","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0035","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/03007995.2017.1421146","article-title":"Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment","volume":"34","author":"Mody","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0036","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/dom.13603","article-title":"Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States","volume":"21","author":"Mody","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0037","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","article-title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide","volume":"19","author":"Alatorre","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0038","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s13300-021-01053-7","article-title":"Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting","volume":"12","author":"Uzoigwe","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0039","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/13696998.2019.1609482","article-title":"Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy","volume":"22","author":"Boye","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.clinthera.2020.06.006","article-title":"The unmet medical needs of current injectable antidiabetic therapies in china: patient and health care professional perspectives","volume":"42","author":"Chen","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.04.005_bib0041","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JAC.0000000000000379","article-title":"Cardiovascular disease in patients with type 2 diabetes: a qualitative analysis of knowledge, attitudes, and beliefs of health care professionals","volume":"44","author":"Ciemins","year":"2021","journal-title":"J Ambul Care Manage"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:05Z","timestamp":1758963425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0149291822001448"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.04.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}